Coya Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · +0.47%
- Market cap
- $75.77M
- 23.46M shares
- Filings
- 232
Q3 2026+123.6% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
—
—
—Q3 2026N/M FY25 yoy
Q3 2026+22.1% FY25 yoy
- $75.77M
- —
- 16.2×
- 2.3×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $7,945,753 | reported | |
| FY 2024 | 2024-12-31 | $3,554,061 | reported | |
| FY 2023 | 2023-12-31 | $6,002,206 | reported | |
| FY 2022 | 2022-12-31 | $0 | reported |
Pharmaceutical preparations
Coya Therapeutics, Inc. is the 176th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
BIOABioAge Labs, Inc.$9.0M—896.1%$260.1MROIVRoivant Sciences Ltd.$8.3M71.6%3,629.2%$29.0B
COYACoya Therapeutics, Inc. (this company)$7.9M123.6%267.1%$75.8M
ACRSAclaris Therapeutics, Inc.$7.8M58.2%829.6%$635.2MBOLTBolt Biotherapeutics, Inc.$7.7M0.1%433.7%$12.6MADAGAdagene Inc.$7.7M7,332.8%229.6%—XENEXenon Pharmaceuticals Inc.$7.5M—4,612.1%$4.0BOVIDOvid Therapeutics Inc.$7.3M1,181.3%240.1%$479.4MWHWKWhitehawk Therapeutics, Inc.$7.1M72.5%288.3%$181.7MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Coya Therapeutics, Inc. · CIK 1835022 · Engraved from SEC EDGAR